Key result
IV cangrelor for acute neuroendovascular procedures was feasible, with 1 thrombotic event, 3 bleeding events, and 75% of discharged patients achieving a good 90-day functional outcome.
Why the study?
Dual antiplatelet therapy in the acute phase of neuroendovascular procedures can be challenging, prompting evaluation of the feasibility and safety of intravenous cangrelor.
Is intravenous cangrelor safe and feasible as an antiplatelet treatment during acute neuroendovascular surgery procedures?
Observational (n=10)
Is intravenous cangrelor safe and feasible as an antiplatelet treatment during acute neuroendovascular surgery procedures?
Intravenous cangrelor is a feasible antiplatelet treatment option for acute neuroendovascular procedures, though it carries inherent risks of bleeding and thrombosis in this critically ill population.
Answers are grounded in this paper and cite their sources.
May support cangrelor as DAP alternative in acute neurointerventions; leaves open need for prospective trials before practice change.
BACKGROUND: Dual antiplatelet therapy (DAP) is necessary to prevent thromboembolic events during carotid stenting, stent-assisted coil embolization, and implant of flow diverters (FD). However, DAP in the acute phase may be challenging. An intravenous alternative, cangrelor, has rapid onset, short plasma half-life, and more reliable antiplatelet action for acute interventions. The study objective was to evaluate feasibility and safety of IV cangrelor during acute neuroendovascular surgery procedures. METHODS: We performed a retrospective analysis of our database of patients treated with stent-assisted coil embolization, FD placement for aneurysmal subarachnoid hemorrhage (aSAH), or stenting for acute internal carotid artery (ICA) occlusion where IV cangrelor was used. Morbidity, mortality, incidence of thromboembolic events, hemorrhages, and 90-day outcomes were reported. RESULTS: Ten patients were found in our database from June 2018 through January 2019. Four patients had aSAH, four had middle cerebral artery strokes with tandem lesions, one had an ICA occlusion, and one had a vertebral artery aneurysm. One of the ten patients experienced a thrombotic event. One patient developed new post-procedural bleeding and two had worsening intracranial hemorrhage. Five patients were discharged home in stable condition, two to acute rehabilitation, one to a nursing facility, and two others expired (likely the result of the severe and evolving strokes). Of the eight who were discharged, six (75%) had a good 90-day functional outcome (modified Rankin Scale 0-2). CONCLUSION: Acute administration of IV cangrelor with or without oral ticagrelor is a feasible antiplatelet treatment option for acute neuroendovascular procedures.
No takes yet. Share an insight, caveat, or question.
Linfante et al. (2020) conducted an observational in Acute neuroendovascular surgery procedures (n=10). IV cangrelor was evaluated on Feasibility and safety (morbidity, mortality, thromboembolic events, hemorrhages, and 90-day outcomes). IV cangrelor for acute neuroendovascular procedures was feasible, with 1 thrombotic event, 3 bleeding events, and 75% of discharged patients achieving a good 90-day functional outcome.
Synapse has enriched 10 related papers. Consider them for comparative context: